Fortunately, the advent of TKIs targeting BCR::ABL1 dramatically improved survival and now forms the foundation of therapy for Ph-positive B-ALL (as recently reviewed elsewhere [26]). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.